Delving into the Latest Updates on Azilsartan Kamedoxomil with Synapse

主要研究目的：研究空腹/餐后状态下单次口服受试制剂美阿沙坦钾片（规格：80mg，山东药石制药有限公司生产）与参比制剂美阿沙坦钾片（商品名易达比®，规格：80mg；Takeda Ireland Ltd.生产）在健康受试者体内的药代动力学，评价空腹/餐后状态口服两种制剂的生物等效性。次要研究目的：评估受试制剂美阿沙坦钾片（规格：80mg）与参比制剂易达比®（规格：80mg）在健康受试者中的安全性。

[Translation]

The main purpose of the study is to study the pharmacokinetics of the test preparation, Asartan Potassium Tablets (Specification: 80 mg, produced by Shandong Yaoshi Pharmaceutical Co., Ltd.) and the reference preparation, Asartan Potassium Tablets (trade name Edabi®, specification: 80 mg; produced by Takeda Ireland Ltd.) in healthy subjects after a single oral administration in the fasting/postprandial state, and to evaluate the bioequivalence of the two preparations in the fasting/postprandial state. Secondary purpose of the study: to evaluate the safety of the test preparation, Asartan Potassium Tablets (Specification: 80 mg) and the reference preparation, Edabi® (Specification: 80 mg) in healthy subjects.

Start Date13 May 2024

Sponsor / Collaborator

Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology Co., Ltd.

CTR20240854 / CompletedNot Applicable

美阿沙坦钾片在健康受试者中空腹和餐后状态下的单剂量、随机、开放、两周期、两序列、自身交叉设计的生物等效性试验

[Translation] A single-dose, randomized, open-label, two-period, two-sequence, self-crossover bioequivalence study of Asartan Potassium Tablets in healthy subjects under fasting and fed conditions

研究空腹和餐后状态下单次口服受试制剂美阿沙坦钾片（规格：80mg，浙江昂利康制药股份有限公司）与参比制剂美阿沙坦钾片（商品名：易达比®，规格：80mg，Takeda Pharma A/S）在健康成年受试者体内的药代动力学，评价空腹和餐后口服两种制剂的生物等效性。

[Translation]

The pharmacokinetics of the test preparation, Asartan Potassium Tablets (Specification: 80 mg, Zhejiang Anlikang Pharmaceutical Co., Ltd.) and the reference preparation, Asartan Potassium Tablets (Trade name: Edabi®, Specification: 80 mg, Takeda Pharma A/S) were studied in healthy adult subjects after a single oral administration in the fasting and fed state, and the bioequivalence of the two preparations after fasting and fed oral administration was evaluated.

Start Date11 May 2024

Sponsor / Collaborator

Zhejiang Anglikang Pharmaceutical Co. Ltd.

CTR20241086 / CompletedNot Applicable

美阿沙坦钾片在中国健康受试者中的一项随机、开放、空腹和餐后单次给药、两制剂、两周期双交叉的人体生物等效性试验

[Translation] A randomized, open-label, single-dose, fasting and fed, two-formulation, two-period, double-crossover bioequivalence study of Asartan Potassium Tablets in healthy Chinese subjects

观察单次口服80 mg（空腹/餐后）受试制剂美阿沙坦钾片（规格：80 mg/片）与参比制剂美阿沙坦钾片（易达比？，规格：80 mg/片）在中国健康人体的相对生物利用度，分析两种制剂的药代动力学参数，评价两制剂的生物等效性和安全性，为该药的申报及临床用药提供参考依据。

[Translation]

To observe the relative bioavailability of a single oral dose of 80 mg (fasting/after meal) of the test preparation, Asartan Potassium Tablets (specification: 80 mg/tablet) and the reference preparation, Asartan Potassium Tablets (Edarbi®, specification: 80 mg/tablet) in healthy Chinese volunteers, analyze the pharmacokinetic parameters of the two preparations, evaluate the bioequivalence and safety of the two preparations, and provide a reference for the application and clinical use of the drug.

Start Date02 Apr 2024

Sponsor / Collaborator

Beijing Baiao Pharmaceuticals Co., Ltd.

100 Clinical Results associated with Azilsartan Kamedoxomil

Login to view more data

100 Translational Medicine associated with Azilsartan Kamedoxomil

Login to view more data

100 Patents (Medical) associated with Azilsartan Kamedoxomil

Login to view more data

666

Literatures (Medical) associated with Azilsartan Kamedoxomil

31 Dec 2024·Journal of enzyme inhibition and medicinal chemistry

Acetazolamide and human carbonic anhydrases: retrospect, review and discussion of an intimate relationship

Review

Author: Tsikas, Dimitrios

Acetazolamide (AZM) is a strong pharmacological sulphonamide-type (R-SO₂-NH₂, pK_a 7.2) inhibitor of the activity of several carbonic anhydrase (CA) isoforms, notably of renal CA II (K_i, 12 nM) and CA IV (K_i, 74 nM). AZM is clinically used for about eighty years in various diseases including epilepsy and glaucoma. Pharmacological AZM increases temporarily the urinary excretion of bicarbonate (HCO₃^-) and sodium ions (Na⁺) and sustainably the urinary pH. AZM is excreted almost unchanged over several hours at high rates in the urine. Closely parallel concentrations of circulating and excretory AZM are observed upon administration of therapeutical doses of AZM. In a proof-of-principle study, we investigated the effects of the ingestion of a 250-mg AZM-containing tablet by a healthy volunteer on the urinary excretion of organic and inorganic substances over 5 h (range, 0, 0.5, 1, 1.5, 2, 3, 4, 5 h). Measured analytes included: AZM, amino acids and their metabolites such as guanidinoacetate, i.e. the precursor of creatine, of asymmetrically (ADMA) and symmetrically (SDMA) dimethylated arginine, nitrite (O = N-O^-, pK_a 3.4) and nitrate (O₂N-O^-, pK_a -1.37), the major metabolites of nitric oxide (NO), the C-H acidic malondialdehyde (MDA; (CHO)₂CH₂, pK_a 4.5), and creatinine for correction of analytes excretion. All analytes were measured by validated isotopologues using gas chromatography-mass spectrometry (GC-MS) methods. AZM excretion in the urine reached its maximum value after 2 h and was fairly stable for the next 3 h. Time series analysis by the ARIMA method was performed. AZM ingestion increased temporarily the urinary excretion of the amino acids Leu + Ile, nitrite and nitrate, decreased temporarily the urinary excretion of other amino acids. AZM decreased sustainably the urinary excretion of MDA, a biomarker of oxidative stress (i.e. lipid peroxidation). Whether this decrease is due to inhibition of the excretion of MDA or attenuation of oxidative stress by AZM is unknown. The acute and chronic effects of AZM on the urinary excretion of electrolytes and physiological substances reported in the literature are discussed in depth in the light of its extraordinary pharmacokinetics and pharmacodynamics. Tolerance development/drug resistance to AZM in chronic use and potential mechanisms are also addressed.

01 Mar 2024·Journal de mycologie medicale

Pythium insidiosum: In vitro oomicidal evaluation of telithromycin and interactions with azithromycin and amorolfine hydrochloride

Article

Author: Maciel, Aline Fontanella ; Ianiski, Lara Baccarin ; Botton, Sônia de Avila ; Sangioni, Luis Antônio ; Pal, Mahendra ; Pereira, Daniela Isabel Brayer ; Colla, Ana Carolina Nolasco ; Braga, Caroline Quintana ; Santurio, Janio Morais

This study evaluated the repositioning of the ketolide antibacterial telithromycin (TLT) against the oomycete Pythium insidiosum and verified the combination of TLT and the antimicrobials azithromycin (AZM) and amorolfine hydrochloride (AMR), which have known anti-P. insidiosum activity. Susceptibility tests of P. insidiosum isolates (n = 20) against the drugs were carried out according to CLSI protocol M38-A2, and their combinations were evaluated using the checkerboard microdilution method. The minimum inhibitory concentrations were 0.5-4 µg/mL for TLT, 2-32 µg/mL for AZM, and 16-64 µg/mL for AMR. For the TLT+AZM combination, 52.75 % of interactions were indifferent, 43.44 % were antagonistic, and 9.70 % were synergistic. As for interactions of the TLT+AMR combination, 60.43 % were indifferent, 39.12 % were antagonistic, and 10.44 % synergistic interactions. This study is the first to evaluate the repositioning of the antibacterial TLT against mammalian pathogenic oomycetes, and our results show that its isolated action is superior to its combinations with either AZM or AMR. Therefore, we recommend including TLT in future research to evaluate therapeutic approaches in different clinical forms of human and animal pythiosis.

01 Mar 2024·Chemosphere

Understanding the photo-sensitive essence of organic-inorganic hybrids for the targeted detection of azithromycin

Article

Author: E S, Erakulan ; Yazhini, Crescentia ; Neppolian, B ; Thapa, Ranjit

Being a macrolide antibiotic, the antiviral and anti-inflammatory properties of azithromycin (AZM) were taken advantage of during the COVID-19 pandemic which led to the overuse of AZM resulting in excessive release and accumulation in the waterways and ecosystem causing unpleasant threats to humankind. This demands the necessity for a highly sensitive material being capable of recognizing AZM in wastewater. Mindful of the optical attributes of organic ligand structures, we have constructed a hybrid material by chelating Zn²⁺ with pyridyl benzimidazole (PBI). The prepared sensor material ZnPBI was characterized using various microscopic and spectroscopic techniques including XRD, FT-IR, HR-SEM, HR-TEM, etc. The proposed sensor material exhibited proficient detection performance selectively towards AZM with a very low detection limit of 72 nM. Two linear ranges between 0 - 70 μM and 70-100 μM were observed corresponding to two different mechanistic pathways. To the best of our knowledge, the utilization of a metal-organic complex (MOC) for the fluorometric detection of AZM has not been explored so far. It is creditworthy to cite that the long-term structural stability of the sensor material was maintained for 100 days in water and it can be reused three times without any depreciation in the sensing activity. A combination of energy transfer routes, adsorption and electrostatic interactions for AZM detection are described experimentally and theoretically which provides insights into the role of MOC as sensing probes.

1

News (Medical) associated with Azilsartan Kamedoxomil

26 Jul 2017

·www.bioportfolio.com

Arbor Pharmaceuticals LLC Pharmaceuticals Healthcare Deals and Alliances Profile. [Report Updated: 20072017] Prices from USD $250

Summary Arbor Pharmaceuticals LLC Arbor is a healthcare products provider that develops prescription products for the hospital, cardiovascular and pediatric segments. The company offers licensing, manufacturing, development and commercialization of latestage prescription products. It also offers generic prescription and development stage products. Arbor's prescription products comprise edarbi, edarbyclor, bidil, nymalize, eryped, and erythromycin group of products. It offers products used in treatment areas including cardiovascular, emergency, pediatrics, psychiatry and endocrinology diseases. The company offers its products through sales professionals to hospitals and physicians across the US. Arbor is headquartered in Atlanta, Georgia, the US. Arbor Pharmaceuticals LLC Pharmaceuticals Healthcare Deals and Alliances Profile. provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions MAs, partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, subsector and regions. GlobalData derived the data presented in this report from proprietary inhouse Pharma eTrack deals database, and primary and secondary research. Scope Financial Deals Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships. Deals by Year Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period. Deals by Type Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc. Deals by Region Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America. Deals by Subsector Chart and table showing information on the number of deals and value reported by the company, by subsector. Major Deals Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's major public companies key financial metrics and ratios. Business Description A brief description of the company's operations. Key Employees A list of the key executives of the company. Important Locations and Subsidiaries A list and contact details of key centers of operation and subsidiaries of the company. Key Competitors A list of the key competitors of the company. Key Recent Developments A brief on recent news about the company. Reasons to Buy Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period. Understand the company's business segments' expansion / divestiture strategy The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy. Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios. Equip yourself with detailed information about the company's operations to identify potential customers and suppliers. The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors. Stay uptodate on the major developments affecting the company Recent developments concerning the company presented in the profile help you track important events. Gain key insights into the company for academic or business research Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs. Note*: Some sections may be missing if data is unavailable for the company.

Acquisition

100 Deals associated with Azilsartan Kamedoxomil

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	Azilsartan Kamedoxomil	C09CA09	DB08822

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Essential Hypertension	EU	Takeda Pharma A/S	07 Dec 2011
Essential Hypertension	IS	Takeda Pharma A/S	07 Dec 2011
Essential Hypertension	LI	Takeda Pharma A/S	07 Dec 2011
Essential Hypertension	NO	Takeda Pharma A/S	07 Dec 2011
Hypertension	US	Azurity Pharmaceuticals, Inc.	25 Feb 2011

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Diabetes Mellitus, Type 2	Phase 3	US	Takeda Pharmaceutical Co., Ltd.	01 Jan 2012

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02541669 (CTgov)	Phase 1	-	64	TAK-491 (Open Label: TAK-491 40 mg)	toxpeyzfvb(eypndixcjo) = zxvqtcfmeh zzstaobjgz (fswtttyrid, gqtsjszaoo - axjcncixok) View more	-	05 Feb 2020
				TAK-491 (Open Label: TAK-491 80 mg)	toxpeyzfvb(eypndixcjo) = eohadwsatk zzstaobjgz (fswtttyrid, xjaifbgnsj - vvscxlvmam) View more
NCT02517866 (CTgov)	Phase 4	Diabetes Mellitus, Type 2 \| Essential Hypertension	380	Azilsartan Medoxomil	tcfwzwpebj(ytlhxgeqoe) = etyocoucvx wjghhjmpid (nedheransr, ashfshctue - rqcyrbxcrv) View more	-	01 Mar 2019
NCT02480764 (CTgov)	Phase 3	Essential Hypertension	612	Valsartan Placebo+Azilsartan medoxomil (Azilsartan Medoxomil 40 mg)	txiemtfnta(ssmpnlothb) = xpatcnteps ypenlmjdcb (xyhruixjbv, dsanlwnwrg - zhcyiifxzm) View more	-	11 Feb 2019
				Valsartan Placebo+Azilsartan medoxomil (Azilsartan Medoxomil 80 mg)	txiemtfnta(ssmpnlothb) = amundlonjj ypenlmjdcb (xyhruixjbv, mxlbzlemzv - ktctmgvkro) View more
NCT02203916 (CTgov)	Phase 3	Essential Hypertension	328	Azilsartan medoxomil placebo (Placebo)	hcuqfcnpbw(jnnmkbczvh) = gfwdswkpda cwdoliznsy (prkckliyza, eboocawics - tcerybaere) View more	-	19 Dec 2016
				Azilsartan medoxomil (Azilsartan Medoxomil 40 mg)	hcuqfcnpbw(jnnmkbczvh) = pemoiewkcl cwdoliznsy (prkckliyza, olhfaabtrt - oafdrpumxz) View more
NCT00695955 (Pubmed \| Clin Exp Hypertens) Manual	Phase 3	Essential Hypertension	669	chlorthalidone+azilsartan medoxomil	btbbxbwwtn(rbuafvvrkt) = jlbggfkrmh hxiwzgkbuv (koyuwjgrxd ) View more	Positive	01 Jan 2016
				hydrochlorothiazide+azilsartan medoxomil	btbbxbwwtn(rbuafvvrkt) = bfanudcniq hxiwzgkbuv (koyuwjgrxd ) View more
NCT01496430 (CTgov)	Phase 3	Diabetes Mellitus, Type 2 \| Hypertension	105	Placebo (Placebo QD)	zhcafvwyza(idbpizzfma) = hefouojgbz rtemovjqbs (mytqqpyrna, beecadjdqs - bhibngxogr) View more	-	06 May 2015
				Azilsartan medoxomil (Azilsartan Medoxomil 40 mg QD)	zhcafvwyza(idbpizzfma) = wfgfkewbqa rtemovjqbs (mytqqpyrna, edqktedrwc - icudgaqkal) View more
NCT00696384 (Pubmed) Manual	Phase 3	Hypertension	418	Azilsartan Medoxomil	ejiztbfyuk(qwgoyxsaoc): difference = -7.8 (95% CI, -9.8 to -5.8), P-Value = <0.001 View more	Positive	01 Mar 2015
				Azilsartan Medoxomil+Chlorthalidone
NCT00591578 (Pubmed \| J Clin Hypertens (Greenwich))	Phase 3	Essential Hypertension	984	Azilsartan medoxomil (AZL-M)	kwneleoijj(bdzxzkzzma) = uflibfquzk gziovsslmv (xzdemnfsgg )	Positive	01 Jul 2011
				Valsartan (VAL)	kwneleoijj(bdzxzkzzma) = zkunyzuavi gziovsslmv (xzdemnfsgg )
NCT00591578 (CTgov)	Phase 3	Essential Hypertension	984	Azilsartan Medoxomil (Azilsartan Medoxomil 40 mg QD)	rfwtyttqtz(zyjhqehqmz) = butnrznoip sdloqjyqnt (djcvupzzyo, hecmqhuimq - nmvihvcczy) View more	-	19 Apr 2011
				Azilsartan Medoxomil (Azilsartan Medoxomil 80 mg QD)	rfwtyttqtz(zyjhqehqmz) = oeflnupidg sdloqjyqnt (djcvupzzyo, lrfqqbgqad - ziqxahtkeu) View more